Fidson Healthcare Plc has been selected as one of eleven global manufacturers to sign sublicence agreements with the Medicines Patent Pool (MPP) for the production of generic versions of baloxavir marboxil, an innovative influenza antiviral treatment. This initiative, part of a voluntary licensing agreement with Roche, aims to diversify the manufacturing base for influenza treatments across 129 low- and middle-income countries. By localizing production capabilities, the partnership seeks to strengthen regional pandemic preparedness and ensure equitable access to life-saving medicines. Fidson is the only manufacturer representing the African region in this cohort, validating its commitment to world-class pharmaceutical manufacturing.

Fidson Healthcare Plc has been selected by the Medicines Patent Pool (MPP) as one of 11 global manufacturers to produce generic versions of Roche’s influenza treatment, baloxavir marboxil. This voluntary licensing agreement grants Fidson the authority to supply the antiviral across 129 low- and middle-income countries, pending regulatory approval. The initiative aims to diversify global supply chains and enhance regional preparedness for future influenza outbreaks. Fidson’s participation follows a competitive selection process based on technical and regulatory capacity, marking a significant step for the Nigerian pharmaceutical sector in the global health supply chain.

Nigerian stocks listed on the FTSE Russell Frontier Market Index saw significant activity this week, driven by renewed investor interest following Nigeria’s formal return to the index on September 21. Among the 31 constituents, 16 recorded gains, with NAHCO and Fidelity Bank leading the surge. Fidelity Bank also emerged as the most traded stock, recording 893.69 million shares valued at N18.30 billion. Analysts attribute the positive performance in the financial services sector to the recent 350 basis point MPR cut to 23 percent, which is expected to support credit growth and valuations. While foreign interest is anticipated to rise, market experts caution that the full impact of the index reclassification will unfold gradually as institutional investors strategically deploy capital. Total turnover for the index constituents reached 2.21 billion shares worth N120.31 billion, accounting for nearly half of the total market volume for the week.

Nigerian equities rallied during Friday’s trading session, driven by investor optimism following FTSE Russell’s confirmation of thirty-one Nigerian stocks for its Frontier Index Series. This follows Nigeria’s official reclassification to Frontier Market status, effective September 21, 2026. Market analysts expect the transition to improve global visibility, liquidity, and foreign portfolio inflows, particularly for large-cap stocks that meet the index criteria. The NGX All Share Index rose to 247,016 points, with banking sector gains leading the market activity.

The Nigerian stock market extended its recent rally on Monday, August 31, 2026, adding N1.91 trillion in market capitalization. The NGX All-Share Index rose 1.20% to close at 244,199.39 points, lifting the year-to-date return to 56.93%. The positive momentum follows FTSE Russell’s recent reclassification of Nigeria as a Frontier Market. Trading activity was robust, with 606.19 million shares exchanged for N38.70 billion. Banking stocks led the gains, with the Banking Index surging 3.11% as investors reacted to improved market sentiment. 43 stocks advanced while 16 declined.

May & Baker Nigeria Plc led the pharmaceutical sector in profitability for the first half of 2026, achieving a net profit margin of 16.59 percent. While the combined profit margin for five major listed pharma firms rose to 10.24 percent, May & Baker’s performance was distinct because it stemmed from improved cost efficiency rather than top-line revenue growth. Fidson Healthcare followed with a 10.37 percent margin, while MeCure Industries and Neimeth International Pharmaceuticals recorded 7.76 percent and 5.65 percent respectively. Morison Industries trailed the group, posting a net loss for the period.